• Attorneys
  • Practices & Industries
  • Thought Leadership +
    • Videos
    • Podcasts
    • Publications
      • Chemical Law & Prop 65 Blog
    • Webinars
  • News & Events +
    • News
    • Events/
      Speaking Engagements
  • About
  • Careers
  • Diversity
  • Contact
  • Offices
  • Payment Portal +
    • Pay your invoice
    • Pay your retainer
Buchalter
  • About
  • Careers
  • Diversity
  • Contact
  • Offices
  • Attorneys
  • Practices & Industries
  • Thought Leadership +
    • Publications
      • Chemical Law & Prop 65 Blog
    • Webinars
    • Videos
    • Podcasts
  • News & Events +
    • News
    • Events/
      Speaking Engagements
  • Payment Portal +
    • Pay your invoice
    • Pay your retainer
« View All Publications

AI Trends For 2023 - FDA Regulatory

JDSUPRA

December 16, 2022

By: Neusha Etemad

“In September 2022, the U.S. Food & Drug Administration (FDA) released its Clinical Decision Support (CDS) Software Guidance and the final report on the Software Pre-Certification Pilot Program. The new FDA policies move away from prized flexibilities in the previous guidelines governing software products. In the new and final CDS Guidance, FDA modified its interpretation of each of the four criteria in section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act, significantly narrowing what FDA considers exempt from regulatory authority…”

To view the full article, please click here.

Share

Related Attorneys

  • Neusha Etemad
Buchalter footer logo

Adam Bass, Buchalter President & CEO

  • About
  • Careers
  • News & Events
  • Subscribe
  • Denver
  • Los Angeles
  • Napa Valley
  • Orange County
  • Portland
  • Sacramento
  • Salt Lake City
  • San Diego
  • San Francisco
  • Scottsdale
  • Seattle
  • © Copyright 2023 Buchalter, A Professional Corporation
  • Privacy Notice
  • Notice at Collection
  • Do Not Sell or Share PI
Buchalter Communications

We love sharing our knowledge, but we don't want to inundate you. If you would like to receive communications from Buchalter, please highlight the text boxes below indicating which type of communications you would like to receive, and provide your name and email address. [Street address is only necessary for Points and Authorities.] We appreciate your interest in our work.

"*" indicates required fields

Type*
This field is for validation purposes and should be left unchanged.